Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8897 - 8904 of 12091 results

New Energy Investment Initiatives Part of Major Trend
December 2, 2015| Blog| Viewpoint

Supreme Court Rejects States' Request for 30 Day Filing Extension on DACA, DAPA
December 2, 2015| Blog| Viewpoint

Australia Border "SmartGate" Program Expands to US Citizens
December 2, 2015| Blog| Viewpoint

OIG Proposes Alternative Part B Payment Methodologies for 340B Drugs: Is This the End of 340B As We Know It?
December 2, 2015| Blog| Viewpoint

Securities Law Risk Mitigation in EB-5 Offerings
December 1, 2015| Blog| Viewpoint

Borrowers in EB-5 Deals Not Insulated from Securities Litigation by the SEC
December 1, 2015| Blog| Viewpoint

Piercing The Corporate Veil Takes More Than Just Fraud By The Individual
December 1, 2015| Blog| Viewpoint

Professor Coffee and Judge Rakoff Comment on Securities Class Actions
December 1, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
